PhD | Business Development Senior Manager BaseLaunch
Tel. +41 61 295 50 17stephan. emmerth@baselaunch. ch
Vas Narasimhan will be responsible for steering the future of Novartis when he takes over as CEO on 1 February 2018. The successor of Joseph Jimenez is currently Global Head of Drug Development and Chief Medical Officer at the pharmaceutical company.
As Novartis announced on Monday, the newly designated CEO has held several leadership positions in commercial, drug development and strategy roles since joining the Basel-based pharmaceutical company in 2005.
Prior to joining Novartis, Vas Narsimhan worked at McKinsey & Company. Born in 1976, the U.S. citizen has degrees in biological studies and medicine and is an elected member of the U.S. National Academy of Medicine.
Joseph Jimenez’s successor is “deeply anchored in medical science, has significant experience in managing the interfaces between Research and Development and commercial units and has strong business acumen with a track record of outstanding achievements,” said Jörg Reinhardt, Chairman of the Novartis Board of Directors.
“As a physician, he has a strong patient focus and a genuine humane perspective and care for the mission and values of Novartis.”
Joseph Jimenez will step down as CEO on 31 January 2018 and will retire from Novartis on 31 August 2018. Over that eight-month period, the outgoing CEO will be available for advice and support “at the request of the Chairman of the Board of Directors or the CEO”.